Premium
Treatment of unresectable or metastatic osteosarcoma with cisplatin or cisplatin–doxorubicin
Author(s) -
Pratt Charles B.,
Champion John E.,
Senzer Neil,
Green Alexander A.,
Rao Bhaskar,
Douglass Edwin,
Meyer William E.,
Crom Debbie Bowles
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19851015)56:8<1930::aid-cncr2820560806>3.0.co;2-u
Subject(s) - cisplatin , medicine , osteosarcoma , doxorubicin , oncology , chemotherapy , toxicity , surgery , cancer research
Responses and toxicity after treatment with cisplatin and cisplatin–doxorubicin were compared in two groups of patients with unresectable or metastatic osteosarcoma. Complete or partial responses developed in 3 of 18 individuals treated with cisplatin, and in 5 of 19 after the two‐drug combination. Hematologic and gastrointestinal complications were more frequent and severe in patients who received both agents. The combined use of cisplatin and doxorubicin is justified for patients with unresectable or metastatic osteosarcoma at diagnosis because of the potential therapeutic benefits for these individuals. Cancer 56: 1930‐1933, 1985.